It is an actual, not an estimate. They reported a profit before tax of 205m. Net Profit after Tax of 157m. Market Cap of 2.1b less 200m cash is 1.9b AUD.
1900/157 = 12.10
It is from their annual report: Neuren Pharmaceuticals Annual Report 2023 so you can check it yourself.
Yes, if you read what I said. Forward PE is more like 35 depending on the multiplier but there is growth in NA and from 2026 onwards we will be seeing revenue from the EU and Japan.
A total dud is nonsense. And the short report predicted a far lower peak sales number than what we're seeing from NA alone. If we reported a 20-30% decrease in Daybue sales maybe there would be some truth to what you said.
Ann: Q2 2024 update, page-19
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.56 |
Change
-0.400(2.67%) |
Mkt cap ! $1.860B | |||
| Open | High | Low | Value | Volume |
| $14.96 | $15.00 | $14.18 | $7.303M | 503.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 30783 | $14.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.60 | 1006 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |